David Guyer

David Guyer, M.D., joined SV Life Sciences in 2006 and serves on the boards of portfolio companies Link Medicine, Lux Biosciences, NeoVista, Neurotech, and Ophthotech as well as the public company Optos. David co-founded and served as CEO and director of Eyetech Pharmaceuticals Inc. for six years. He led Eyetech – a biopharmaceutical company that specialized in the development and commercialization of novel therapeutics to treat diseases of the eye – through private financing rounds totaling approximately $170 million, a $157 million initial public offering, and secondary financing. The company developed and gained FDA approval for Macugen, the first anti-VEGF treatment approved for macular degeneration. Eyetech partnered with Pfizer in a deal valued at over $750 million. OSI Pharmaceuticals subsequently acquired Eyetech in a deal valued at $935 million. Prior to founding Eyetech, Dr. Guyer was professor and chairman of the department of ophthalmology at the NYU School of Medicine. Dr. Guyer holds a bachelor of science from Yale College and a medical degree from Johns Hopkins Medical School.